Clinical trial NCT01659021 - References

Chronic Lymphocytic Leukemia — Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Citation(s)

•   Flinn I, Kimby E, Cotter FE, Giles FJ, Janssens A, Pulczynski EJ, et al
  A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
•   Jones J, Robak T, Wach M, Brown JR, Menter AR, Vandenberghe E, et al
  Updated results of a phase 3 randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) [Poster 7515]. American
•   Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C
  Efficacy and safety of idelalisib in combination with ofatumumab for
•   Jones JA, Wach M, Robak T, Brown JR, Menter AR, Vanderberghe E, et al
  Results of a Phase 3 Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (IDELA) in Combination with Ofatumumab (OFA) for Previously Treated Chronic Lymphocyt
•   Robak T, Jones J, Wach M, Brown JR, Menter AR, Vandenberghe E, et al
  Updated results of a phase 3 randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) [Poster 213]. 21st Congr
•   Robak T, Wach M, Jones J, Owen C, Brown J, Menter A, et al
  Results Of A Phase 3 Randomized Controlled Study Evaluating The Efficacy And Safety Of Idelalisib (Idela) In Combination With Ofatumumab (Ofa) For Previously Treated Chronic Lymphocytic Leukemia

A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Details for clinical trial NCT01659021